Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease
Background Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease.Methods We present a series of four cases in which administration of rituxima...
Main Authors: | Francisco León Román, Beatriz Pintado-Cort, Diana García-Casado, Francisco Muñiz-González, José Antonio López García-Asenjo, Cristina Díaz-Rodríguez, María Nieves Montoro-López, Mauricio Loucel-Bellino, Beatriz Recio-Moreno, Sara Rebollo-Garrido, Yaiza Martínez-Hernández, Ivan Cusacovich |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-08-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/9/3/e003479.full |
Similar Items
-
Rituximab treatment in patients with systemic sclerosis and interstitial lung disease
by: Abdel Gaffar A Mohammed, et al.
Published: (2017-01-01) -
A rare case of rituximab induced interstitial lung disease
by: Kamal Kant Sahu, et al.
Published: (2016-01-01) -
Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers
by: Fotios Drakopanagiotakis, et al.
Published: (2023-06-01) -
Noninvasive ventilation in acute exacerbation of interstitial lung diseases
by: Naglaa B Ahmed, et al.
Published: (2023-01-01) -
Acute exacerbations of progressive-fibrosing interstitial lung diseases
by: Martin Kolb, et al.
Published: (2018-12-01)